Research programme: antibody therapeutics - Exelixis/Genentech

Drug Profile

Research programme: antibody therapeutics - Exelixis/Genentech

Alternative Names: Anti-DLL4 antibodies; Anti-Notch1-NRR antibodies

Latest Information Update: 10 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis; Genentech
  • Class Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; Notch signalling pathway inhibitors; Notch-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 22 Feb 2011 Discontinued - Preclinical for Solid tumours in USA (Parenteral)
  • 26 Oct 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the adverse events and Cancer pharmacodynamics sections
  • 06 Jul 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top